Replies to post #147314 on Biotech Values

[NP1986]

If you still have trouble convincing others, try capitalizing a few more words.

[mcbio]

…A gold-std. trial in which Peregrine’s Bavituximab is going to AT LEAST DOUBLE **MOS** in 2nd-Line NSCLC = > **MOS** being ULTIMATE ENDPOINT that matters in NSCLC.

This could not be more wrong. MOS doesn't mean much of anything by itself. If PPHM comes back with strong p-values and HR for the bavi arm compared to control, then we may have something to talk about (pending further clarity on the potential concerns pcrutch noted before about possibility that arms may be imbalanced in favor of bavi arm).

[pcrutch]

Stop posting all of this nonsense on this board.

(1) You keep touting some long forgotten biotech exec who ended up at Peregrine.

(2) You all fail to acknowledge who slimy Peregrine has been. Not reporting p-values, hazard ratios,
Also Adam Feuerstein's account of how sneaky Peregrine has been with heavily diluting shareholders thru ATMs. Real quality guys at Peregrine.

http://www.thestreet.com/story/11627155/1/biotech-stock-mailbag-peregrine-pharma.html

(3) Their trials are not gold standard by any means. Maybe if Peregrine had pre-specified the analysis of overall survival, done this with about 3 times as many patients and not used 50% of patients from Russia/India/Ukraine.

(4) IMO, Peregrine has been dishonest about the control arm. Something is up with the baseline levels across arms. PPHM reporting < 6 months strikes me as too unusual. Even the slide below you posted shows 9 months!

Herbst 2010 ("Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial")

"However, in the present study, the median overall survival of 10 months for patients receiving placebo plus docetaxel is longer than that reported in the earlier studies. This difference might be explained by differences in the availability or use of first-line and post-progression therapies, as well as general improvements in standards of care over time."

http://www.sciencedirect.com/science/article/pii/S1470204510701327

Hanna 2004 - 7.9 months
http://bit.ly/Pwt26S

Kim 2008 - 8 months
http://bit.ly/P29m71

(5) You can call me Patrick or Pcrutch. My opinion changed because I eventually caught on to their BS after some conversations with the CEO and further digging. We all can make lapses in judgement on certain companies, since then I have thought quite poorly of the company.